Categories: Market Research

Pruritus Therapeutics Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Pruritus Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Pruritus Therapeutics Market:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

According to The Business Research Company’s Pruritus Therapeutics Global Market Report 2024, The pruritus therapeutics market size has grown strongly in recent years. It will grow from $11.39 billion in 2023 to $12.03 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to growth in incidence of pruritus, diverse causes and conditions, rising aging population, patient quality of life focus..

The pruritus therapeutics market size is expected to see strong growth in the next few years. It will grow to $14.99 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to expanding knowledge of pruritus pathophysiology, innovative drug formulations and delivery, focus on personalized medicine, rise in dermatological research and development, increasing awareness and diagnosis rates, growing interest in botanical and herbal remedies. Major trends in the forecast period include development of itch-specific receptor agonists and antagonists, market emphasis on personalized therapeutic approaches, integration of technology in itch monitoring and management, collaborations for cross-disciplinary research..

The rise in the incidence of dermatological disorders is expected to propel the growth of the pruritus therapeutics market going forward. Dermatological disorders refer to skin, hair, nail, and mucous membrane disorders ranging from acne and eczema to skin cancer and fungal infections. The underlying cause of itching often determines the use of pruritus treatments for dermatological illnesses. This condition uses topical treatments, emollients and moisturizers, immunosuppressant medications, and itching medications. For instance, in January 2022, according to the report published by the American Cancer Society Inc., a US-based voluntary organization for cancer awareness, the estimated cases of skin cancer increased to 108,480106,110 in 2021 , an increase of 5.8% from 100,350 in 2020. Therefore, the rise in the incidence of dermatological disorders is driving the growth of the pruritus therapeutics market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Product innovation is a key trend gaining popularity in the pruritus therapeutics market. Major companies operating in the pruritus therapeutics market focused on developing novel products to strengthen their position in the market. For instance, in August 2021, Fresenius Medical Care AG & Co., a Germany-based product and service provider for people with kidney illnesses, launched KORSUVA (difelikefalin) for a reduction of pruritus related to chronic kidney dysfunction (CKD-aP) in adults having hemodialysis. The Food and Drug Administration (FDA) approved a novel therapeutic injectable drug for managing moderate-to-severe pruritis in patients receiving hemodialysis due to chronic renal failure. It is a first-in-class kappa opioid receptor (KOR) that targets the outer neurological system of the human body. It enhances the safety or effectiveness of the treatment, diagnosis, or prevention of crucial illnesses compared to standard applications.

The pruritus therapeutics market report table of contents includes: